Core Viewpoint - Kingworld Medicines Group (01110) expects a significant decline in profit for the first half of 2025, projecting a year-on-year decrease of approximately 70% to 75% compared to a profit of 45.6 million yuan in the first half of 2024 [1] Financial Performance - The company anticipates a loss attributable to shareholders of approximately 4.5 million yuan for the first half of 2025, while projecting a profit attributable to shareholders of about 30.7 million yuan for the first half of 2024 [1] Business Operations - The board attributes the decrease in profit primarily to a reduction in gross profit of approximately 50% to 55% from its Chinese distribution business for imported pharmaceutical and health products, which is due to a slowdown in market demand for these products [1] - This decline in gross profit is partially offset by an increase in gross profit of about 10% to 15% from Shenzhen Dongdixin Technology Co., Ltd [1]

Core Viewpoint - The company, JinHuo Pharmaceutical Group, anticipates a significant decline in profits for the first half of 2025, projecting a decrease of approximately 70% to 75% compared to the same period in 2024, where profits were reported at 45.6 million yuan [1] Financial Performance - For the first half of 2024, the company reported a profit attributable to owners of approximately 30.7 million yuan [1] - The company expects a loss attributable to owners of about 4.5 million yuan for the first half of 2025 [1] Business Operations - The board attributes the profit decline primarily to a reduction in gross margins of about 50% to 55% in the Chinese distribution business for imported pharmaceutical and health products, driven by a slowdown in market demand [1] - This decline in gross margin is partially offset by an increase in gross margin of approximately 10% to 15% from Shenzhen Dongdixin Technology Co., Ltd [1]

本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，基於本集團截至二零二五年六月三十日止六個月（「本期間」）之未經審核綜合 管理賬目及董事會目前可得的資料之初步評估，本集團預期本期間之本集團溢利 將較截至二零二四年六月三十日止六個月（「前期間」）之人民幣45.6百萬元減少約 70%至75%。 董事會認為本集團溢利減少主要是由於從事品牌進口醫藥及保健產品的中國分銷 業務之毛利減少約50%至55%，主要由於相關產品之需求在市場有所放緩所致。 此減少惟部分給深圳市東迪欣科技有限公司（「東迪欣」）之毛利增加約10%至15% 抵銷所致。 東迪欣，本公司之非全資附屬公司，是一家生產各種醫療設備，包括紅外線探熱 器、手持電動物理治療及復康產品系列的製造商。 基於上文所述，本集團預期與前期間錄得本公司擁有人應佔溢利約人民幣30.7百 萬元相比，本集團本期間將錄得本公司擁有人應佔虧損約人民幣4.5百萬元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損 ...

格隆汇8月14日丨金活医药集团(01110.HK)公告，谨定于2025年8月27日星期三于香港九龙荔枝角道808 号好运工业中心6楼613室会议室举行董事会会议，目的为审议并批准集团截至2025年6月30日止6个月未 经审计中期业绩及建议派付中期股息(如有)，并处理任何其他事项。 ...

承董事會命 金活醫藥集團有限公司 主席 趙利生 香港，二零二五年八月十四日 於本通告日期，執行董事為趙利生先生、陳樂燊女士及周旭華先生；獨立非執行董事為段繼東 先生、黃焯琳先生及儲小平博士。 董事會會議通告 金活醫藥集團有限公司（「本公司」，及其附屬公司，統稱「本集團」）之董事（「董 事」）會（「董事會」）茲通告，謹定於二零二五年八月二十七日星期三於香港九龍荔 枝角道808號好運工業中心6樓613室會議室舉行董事會會議，目的為審議並批准 本集團截至二零二五年六月三十日止六個月之未經審計中期業績及建議派付中期 股息（如有），並處理任何其他事項。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ...

Group 1 - The company has signed a sales agreement with Guangfa Bank and Ping An Bank to sell its fund starting from August 11, 2025 [1][5] - The fund involved is the Invesco Great Wall CSI Hong Kong Stock Connect Innovative Drug ETF Linked Fund [1] - Investors can inquire about details through the company's customer service or the respective banks' websites [3] Group 2 - The company offers a regular investment plan where investors can set up automatic deductions for fund purchases [2] - If the banks open conversion services for the fund, investors must ensure the funds are in redeemable and purchasable states before proceeding [2] - The company may provide fee discounts for one-time or regular investment purchases, subject to the banks' arrangements [2] Group 3 - The company has issued a risk warning regarding the significant premium of its Nasdaq Technology Weighted ETF in the secondary market [5] - If the premium does not decrease effectively by August 11, 2025, the company may apply for temporary trading suspension to alert the market [5] - The fund's trading price is influenced by market supply and demand, systemic risks, and liquidity risks, which may lead to potential losses for investors [5][6]

按照相关规定，各大银行推出信用卡，通常有以下几种还款方式：最低还款，指只需偿还账单上规 定的最低金额，但隐藏着较高的利息成本；分期还款，通常会有年化利率超过10%以上的手续费；全额 还款，这种还款方式在免息期内不收取任何利息。 此外，信用卡提现与刷卡消费存在本质区别，刷卡消费有免息期，但是取现不仅需要支付手续费， 还可能叠加高额利息。 7月16日，广发银行信用卡中心有关负责人回应中新经纬，目前该行已根据行内最新容时政策为客 户提供了减免方案。 在黑猫投诉 【下载黑猫投诉客户端】平台，信用卡相关投诉量已突破39万条，除了逾期利息费用 复杂外，分期和取现等利息成本高等问题成为了信用卡收费投诉的主要问题。 "从未逾期，为啥会产生利息？" 据中新经纬，近日，家住广州的周女士反映，她的广发银行信用卡6年里总共被收取了1.2万利息。 7月15日，广发银行信用卡中心工作人员称，假设还款日是每月7日，在7日当天23：00前还款，正 常情况下是8日到账不会产生利息，23：00后还款就会导致9日才能到账，会产生违约金和消费利息。但 在周女士看来，即便是还款次日或再顺延一日还款到账，也应该有"宽限期"。 2024年5月，中国银行业 ...

Group 1 - The company announced that Mr. Zhang Jianbin has submitted his resignation as an independent non-executive director, effective from August 1, 2025, to allocate more time to his other private affairs [1] - Following Mr. Zhang's resignation, Dr. Chu Xiaoping has been appointed as the chairman of the remuneration committee, effective from August 1, 2025 [1]

Core Viewpoint - Kingworld Medicines Group (01110) announced the resignation of Mr. Zhang Jianbin as an independent non-executive director, effective from August 1, 2025, to allocate more time to his other private affairs [1] Summary by Sections - Resignation Announcement - Mr. Zhang Jianbin has submitted his resignation as an independent non-executive director, chairman of the remuneration committee, member of the audit committee, and member of the nomination committee [1] - Succession Plan - Following Mr. Zhang's resignation, Dr. Chu Xiaoping has been appointed as the chairman of the remuneration committee, effective from August 1, 2025 [1]

Group 1 - The core point of the article is the resignation of Zhang Jianbin from his positions as an independent non-executive director, chairman of the remuneration committee, member of the audit committee, and member of the nomination committee of Golden Healthcare Group, effective from August 1, 2025 [1] Group 2 - The resignation is attributed to Zhang Jianbin wanting to dedicate more time to his other private affairs [1]